Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma
Latest Information Update: 08 Feb 2025
Price :
$35 *
At a glance
- Drugs Lenalidomide (Primary) ; Obinutuzumab (Primary) ; Umbralisib (Primary) ; Bendamustine; Cyclophosphamide; Doxorubicin; Prednisone; Vincristine
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 17 Jul 2024 Status changed from recruiting to active, no longer recruiting.
- 16 Apr 2024 Planned End Date changed from 30 Jun 2024 to 31 Dec 2025.
- 16 Apr 2024 Planned primary completion date changed from 30 Jun 2024 to 31 Dec 2025.